LitAlert ~~ GeneLit.com

    • Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.
    • Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X.
    • Aging (Albany NY). 2020 Nov 30;12. doi: 10.18632/aging.202152. Epub ahead of print.
    • Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
    • Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL.
    • Nat Commun. 2020 Nov 30;11(1):6118. doi: 10.1038/s41467-020-19961-w.
    • Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    • Hao J, Liu Y, Zhang T, He J, Zhao H, An R, Xue Y.
    • Crit Rev Oncol Hematol. 2020 Nov 19;157:103145. doi: 10.1016/j.critrevonc.2020.103145. Epub ahead of print.